%0 Journal Article
%T Hepatitis B and Hepatitis C among Human Immunodeficiency Virus Infected Patients at a District Hospital in Mwanza, Tanzania
%A Mariam M. Mirambo
%A Benson R. Kidenya
%A Vitus Silago
%A Emmanuel Mkumbo
%A Awadh Mujuni
%A Kennedy J. Mmanga
%A Japhet J. Mwihambi
%A Shimba Henerico
%A Carolyne A. Minja
%A Stephen E. Mshana
%J World Journal of AIDS
%P 1-10
%@ 2160-8822
%D 2019
%I Scientific Research Publishing
%R 10.4236/wja.2019.91001
%X Human
immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus
(HCV) infections have been a major public health problem. HIV patients with HBV
and HCV infection are at high risk of liver diseases which is associated with
increased mortality. This study aims at determining the prevalence of hepatitis
B surface antigen (HBsAg), HCV antibodies and HBV antibodies (anti-HBsAg) among
HIV seropositive adults attending care and treatment clinic at Sengerema
district hospital in Mwanza, Tanzania. A cross-sectional hospital based study
was conducted between February and March 2017 among 243 HIV adult patients at
Sengerema designated district hospital, Mwanza, Tanzania. Socio-demographic and
other relevant information were collected using pre-tested questionnaires.
Detection of HBsAg and HCV antibodies was done by commercial rapid
immunochromatographic test while the detection of anti-HBsAg was done using
enzyme linked immunosorbent assay. Data w</span><span style=\"font-family:Verdana;\">ere</span><span style=\"font-family:Verdana;\"> analyzed by using STATA version 13.</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">The
median age of the study participants was 43, interquartile range (IQR): 37</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">-</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">51
years. The majority 172</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">(70.8)
of study participants were female and the majority (88%) of participants had
CD4 count of greater than 200 counts/¦Ěl. </span><span style=\"font-family:Verdana;\">The
prevalence of HBsAg, HCV antibodies and anti-HBsAg were 26/243 (10.7%, 95%
confidence interval [CI]:</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">7</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">-</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">14), </span><span style=\"font-family:Verdana;\">20/243 (8.2%, 95% CI:</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">4.7</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">-</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">11.6)
and (100/243) 41.2%, 95% CI:</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">35</span><span style=\"font-family:&quot;\"> </span><span
%K Hepatitis B
%K Hepatitis C
%K HIV
%K Sengerema
%K Tanzania
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=90070